Evaluation of NT PRO BNP Guided Therapy on Hospitalization Rate and Mortality in Patients With Chronic HF NYHA II-IY

This study has been completed.
Sponsor:
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT00469001
First received: May 2, 2007
Last updated: September 12, 2010
Last verified: September 2010
  Purpose

To use continuous measurement of NT Pro BNP level as guide in therapy patients with CHF.


Condition Intervention Phase
Chronic Heart Failure
Procedure: Treatment according NT Pro BNP level
Phase 1

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Phase 1 Study of Using BNP as Guided Parameter in Treatment HF

Resource links provided by NLM:


Further study details as provided by Hillel Yaffe Medical Center:

Enrollment: 108
Study Start Date: June 2007
Study Completion Date: March 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Detailed Description:

Group of 100 patients with CHF, NYHA II-IY will be followed for 1 years in outpatient clinic of our hospital for hospitalization, death, 6 min walking protocol, number of decompensation as a primary end point. 50 patients will be treated according usual practice in outpatient clinics and in 50 patients will be additionally used level of NT Pro BNP as additional parameter.If level NT Pro BNP will be goes down will not be changes in treatment regiment. If level of NT Pro BNP will be increased treatment will be intensified.At the end of 1 year follow up we will compare the result of two strategies.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with chronic heart failure. Half of the patients were treated by common medical practice for patients with heart failure. The other half were treated according to BNP values and common medical practice.

Criteria

Inclusion Criteria:

  • Patient older 18 y.old with CHF NYHA II-IY.

Exclusion Criteria:

  • All conditions with life expectancy less than 2 years.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00469001

Locations
Israel
Hillel Yaffe Medical Center
Hadera, Israel, 38100
Sponsors and Collaborators
Hillel Yaffe Medical Center
Investigators
Principal Investigator: Michael Shochat, MD, PhD Hillel Yaffe Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00469001     History of Changes
Other Study ID Numbers: 00001
Study First Received: May 2, 2007
Last Updated: September 12, 2010
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hillel Yaffe Medical Center:
Hospitalization and death from exacerbation CHF.

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on April 15, 2014